Evaluation of electrochemotherapy in the management of apocrine gland anal sac adenocarcinomas in dogs: A retrospective study.
Anal gland anal sac adenocarcinoma
bleomycin
cisplatin
dog
electrochemotherapy
Journal
Open veterinary journal
ISSN: 2218-6050
Titre abrégé: Open Vet J
Pays: Libya
ID NLM: 101653182
Informations de publication
Date de publication:
Historique:
received:
13
11
2020
accepted:
18
01
2021
entrez:
26
4
2021
pubmed:
27
4
2021
medline:
5
10
2021
Statut:
ppublish
Résumé
Electrochemotherapy (ECT) combines the administration of anticancer drugs with the delivery of electric pulses, thus increasing the drug uptake through the cell membranes, resulting in increased efficacy. The aim of our study was to describe the tolerability and efficacy of ECT alone or in association with other treatment modalities for the management of apocrine gland anal sac adenocarcinoma (AGASAC). Medical records of dogs with a diagnosis of AGASAC that were treated with ECT alone or in combination with surgery/chemotherapy were retrospectively evaluated. Each dog received 20 mg/m Ten dogs were enrolled in the study. Of those 10 dogs, only one received ECT for treatment of microscopic local disease, while in six cases ECT was the only treatment modality. In three dogs, ECT was followed by systemic medical treatment. Six dogs (60%) had a partial response (PR), three dogs (30%) had stable disease, and one dog treated for microscopic disease did not show any sign of local relapse for 305 days after treatment, being still alive and in complete remission at the time of writing this article. The median time to progression was 303 days and the median survival time was 365 days. The treatment was well tolerated and local side effects were minimal. No systemic effects were documented. This preliminary study suggests that ECT may be beneficial for dogs with AGASAC and could be a useful addition to the current therapeutic options in consideration of its low cost, limited toxicity, and ease of administration.
Sections du résumé
Background
Electrochemotherapy (ECT) combines the administration of anticancer drugs with the delivery of electric pulses, thus increasing the drug uptake through the cell membranes, resulting in increased efficacy.
Aim
The aim of our study was to describe the tolerability and efficacy of ECT alone or in association with other treatment modalities for the management of apocrine gland anal sac adenocarcinoma (AGASAC).
Methods
Medical records of dogs with a diagnosis of AGASAC that were treated with ECT alone or in combination with surgery/chemotherapy were retrospectively evaluated. Each dog received 20 mg/m
Results
Ten dogs were enrolled in the study. Of those 10 dogs, only one received ECT for treatment of microscopic local disease, while in six cases ECT was the only treatment modality. In three dogs, ECT was followed by systemic medical treatment. Six dogs (60%) had a partial response (PR), three dogs (30%) had stable disease, and one dog treated for microscopic disease did not show any sign of local relapse for 305 days after treatment, being still alive and in complete remission at the time of writing this article. The median time to progression was 303 days and the median survival time was 365 days. The treatment was well tolerated and local side effects were minimal. No systemic effects were documented.
Conclusion
This preliminary study suggests that ECT may be beneficial for dogs with AGASAC and could be a useful addition to the current therapeutic options in consideration of its low cost, limited toxicity, and ease of administration.
Identifiants
pubmed: 33898290
doi: 10.4314/ovj.v11i1.15
pii: OVJ-11-100
pmc: PMC8057221
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100-106Déclaration de conflit d'intérêts
Enrico P. Spugnini and Alfonso Baldi are the stockholders of Biopulse S.r.l.
Références
J Vet Intern Med. 2015 Sep-Oct;29(5):1368-75
pubmed: 26192904
Open Vet J. 2019 Apr;9(1):88-93
pubmed: 31086772
In Vivo. 2008 Jan-Feb;22(1):47-9
pubmed: 18396781
Anticancer Res. 2005 Mar-Apr;25(2A):839-45
pubmed: 15868917
J Vet Intern Med. 2009 May-Jun;23(3):514-9
pubmed: 19658207
Vet Comp Oncol. 2018 Dec;16(4):518-528
pubmed: 29961964
Vet Clin North Am Small Anim Pract. 2019 Sep;49(5):967-979
pubmed: 31176458
Vet Comp Oncol. 2016 Mar;14(1):67-80
pubmed: 26811974
J Am Vet Med Assoc. 2015 Apr 15;246(8):877-84
pubmed: 25835172
Vet Comp Oncol. 2017 Sep;15(3):1073-1086
pubmed: 27278807
Vet Pathol. 1981 Jul;18(4):454-71
pubmed: 7257088
Vet Comp Oncol. 2017 Sep;15(3):840-851
pubmed: 26991552
Curr Cancer Drug Targets. 2016;16(1):43-52
pubmed: 26712353
J Vet Intern Med. 2007 Mar-Apr;21(2):274-80
pubmed: 17427388
J Am Vet Med Assoc. 2018 Jul 1;253(1):84-91
pubmed: 29911942
Lab Invest. 1983 Apr;48(4):428-35
pubmed: 6300551
Vet Comp Oncol. 2015 Sep;13(3):176-83
pubmed: 23534501
Vet Comp Oncol. 2016 Dec;14(4):417-446
pubmed: 28530307
J Am Vet Med Assoc. 2019 Apr 15;254(8):960-966
pubmed: 30938616
J Cell Physiol. 2017 Mar;232(3):490-495
pubmed: 27464761
J Small Anim Pract. 2017 May;58(5):263-268
pubmed: 28245066
J Exp Clin Cancer Res. 2003 Dec;22(4):571-80
pubmed: 15053299
Vet Comp Oncol. 2003 Jun;1(2):94-104
pubmed: 19379321
J Vet Intern Med. 2011 Mar-Apr;25(2):407-11
pubmed: 21382075